Current Report · Items 7.01, 9.01 · 8-K

NeOnc Technologies Holdings, Inc.

NTHINASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Aug 13, 2026Accepted Aug 13, 2026, 5:21 PM EDTCIK 1979414Accession 0001829126-26-008773

Company context

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

Current securities

NTHINASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item Regulation 7.01. FD Disclosure. On August 12, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) hosted an investor conference call to discuss results from the Phase 2a portion of NEO100-01. Furnished as Exhibit 99.1 hereto is a transcript of the investor conference call. The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) neonctechnologies_ex99-1.htm

EX-99.1 2 neonctechnologies_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Transcript of NeOnc Technologies Holdings, Inc. NeOnc Technologies August 12, 2026 Participants Keithly Garnett - Chief Financial Officer, NeOnc Technologies Holdings, Inc. Amir Heshmatpour - CEO, Executive Chairman, and President, NeOnc Technologies Holdings, Inc. Thomas Chen - Founder, CSO, Board Director, NeOnc Technologies Holdings, Inc. Josh Neman - Chief Clinical Officer, NeOnc Technologies Holdings, Inc. Jim Delshad - Board Director, NeOnc Technologies Holdings, Inc. Alexandra Miller - Scientific Advisory Board Member, NeOnc Technologies Holdings, Inc. Henry Friedman - Scientific Chair of the Scientific Advisory Board, NeOnc Technologies Holdings, Inc. Analysts Presentation Operator Keithly Garnett - Chief Financial Officer, NeOnc Technologies Holdings, Inc. Thank you, and good morning, everyone. Welcome to the NeOnc Technologies Investor Conference Call to discuss top-line results from the Phase 2a portion of our NEO100-01 clinical trial in recurrent IDH1 mutant high-grade glioma. Joining me on the call today, we have Amir Heshmatpour, our Chief Executive Officer and Executive Chairman. W…

Open exhibit ↗